Gagnon Robert E. sold $23K of IRD
Gagnon Robert E. (Chief Financial Officer) sold 7,783 shares of Opus Genetics, Inc. (IRD) at $2.95 on 2026-07-23.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale of 7,783 shares at $2.9477 on 2026-07-23, filed on 2026-07-27. It does not include any accompanying corporate event, guidance change, or material development.
Market read
Primarily a sentiment/positioning datapoint; likely low incremental impact versus company fundamentals.
What to watch
The filing notes no 10b5-1 plan and provides only the sale size and price; without follow-on purchases or broader insider pattern, inference is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Opus Genetics, Inc. (IRD).
Ticker impact
Opus Genetics CFO Robert E. Gagnon sold 7,783 shares in an open-market transaction on 2026-07-23 at $2.9477.
Low likelihood of a sustained price impact; any reaction is likely short-lived and sentiment-driven.
The filing is a Form 4 insider transaction, but it provides no new operational, financial, or regulatory information beyond the sale details.
Market effects
Minimal; single insider sale does not change sector fundamentals or risk outlook.
Minimal; no broader market or regional catalyst is described.
Minimal; the disclosure is company-specific and not tied to global events.
Counterpoint
Some traders may interpret insider selling as a mild negative signal, especially if paired with other recent insider activity, but this article alone lacks that context.
Key entities
- issuerOpus Genetics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderRobert E. Gagnon
Chief Financial Officer who sold shares via open-market sale.
